Lindsay, MA. Target discovery. Nat Rev Drug Discov 2003, 2:831–838.
Alexander, JC, Salazar, DE. Modern drug discovery and development. In: Robertson, D, ed. Clinical and Translational Science: Principles of Human Research. London: Academic Press; 2009, 361–380.
DiMasi, JA, Hansen, RW, Grabowski, HG. The price of innovation: new estimates of drug development costs. J Health Econ 2003, 22:151–185.
Adams, CP, Brantner, VV. Spending on new drug development. Health Econ 2010, 19:130–141.
Ledford, H. Translational research: 4 ways to fix the clinical trial. Nature 2011, 477:526–528.
Fox, S, Farr‐Jones, S, Sopchak, L, Boggs, A, Nicely, HW, Khoury, R, Biros, M. High‐throughput screening: update on practices and success. J Biomol Screen 2006, 11:864–869.
Williams, M. Systems and integrative biology as alternative guises for pharmacology: prime time for an iPharm concept? Biochem Pharmacol 2005, 70:1707–1716.
Rawlins, MD. Cutting the cost of drug development? Nat Rev Drug Discov 2004, 3:360–364.
Orloff, J, Douglas, F, Pinheiro, J, Levinson, S, Branson, M, Chaturvedi, P, Ette, E, Gallo, P, Hirsch, G, Mehta, C, et al. The future of drug development: advancing clinical trial design. Nat Rev Drug Discov 2009, 8:949–957.
Querec, TD, Akondy, RS, Lee, EK, Cao, W, Nakaya, HI, Teuwen, D, Pirani, A, Gernert, K, Deng, J, Marzolf, B, et al. Systems biology approach predicts immunogenicity of the yellow fever vaccine in humans. Nat Immunol 2009, 10:116–125.
Food and Drug Administration CfDEaRC, CDER Science Prioritization and Review Committee (SPaRC), Identifying CDER`s science and research needs report, 2011.
Barabasi, AL, Gulbahce, N, Loscalzo, J. Network medicine: a network‐based approach to human disease. Nat Rev Genet 2011, 12:56–68.
Fitzgerald, JB, Schoeberl, B, Nielsen, UB, Sorger, PK. Systems biology and combination therapy in the quest for clinical efficacy. Nat Chem Biol 2006, 2:458–466.
Loscalzo, J. Personalized cardiovascular medicine and drug discovery: time for a new paradigm. Circulation 2012, 125:638–645.
Mattick, JS. RNA regulation: a new genetics? Nat Rev Genet 2004, 5:316–323.
Drazen, JM, Silverman, EK, Lee, TH. Heterogeneity of therapeutic responses in asthma. Br Med Bull 2000, 56:1054–1070.
Malmstrom, K, Rodriguez‐Gomez, G, Guerra, J, Villaran, C, Pineiro, A, Wei, LX, Seidenberg, BC, Reiss, TF. Oral montelukast, inhaled beclomethasone, and placebo for chronic asthma. A randomized, controlled trial. Montelukast/Beclomethasone Study Group. Ann Intern Med 1999, 130:487–495.
Haselkorn, T, Chen, H, Miller, DP, Fish, JE, Peters, SP, Weiss, ST, Jones, CA. Asthma control and activity limitations: insights from the Real‐world Evaluation of Asthma Control and Treatment (REACT) study. Ann Allergy Asthma Immunol 104:471–477.
Gamble, J, Stevenson, M, McClean, E, Heaney, LG. The prevalence of nonadherence in difficult asthma. Am J Respir Crit Care Med 2009, 180:817–822.
Spear, BB, Heath‐Chiozzi, M, Huff, J. Clinical application of pharmacogenetics. Trends Mol Med 2001, 7:201–204.
Sorger, PK, Allerheiligen, SRB, Abernethy, DR, Altman, RB, Brouwer, KLR, Califano, A, D`Argenio, DZ, Iyengar, R, Jusko, WJ, Lalonde, R, et al. Quantitative and systems pharmacology in the post‐genomic era: new approaches to discovering drugs and understanding therapeutic mechanisms, An NIH White Paper by the QSP Workshop Group, 2011.
Weiss, ST, Litonjua, AA, Lange, C, Lazarus, R, Liggett, SB, Bleecker, ER, Tantisira, KG. Overview of the pharmacogenetics of asthma treatment. Pharmacogenom J 2006, 6:311–326.
Yao, Z, Hoffman, EP, Ghimbovschi, S, Dubois, DC, Almon, RR, Jusko, WJ. Mathematical modeling of corticosteroid pharmacogenomics in rat muscle following acute and chronic methylprednisolone dosing. Mol Pharm 2008, 5:328–339.
Lander, ES. The new genomics: global views of biology. Science 1996, 274:536–539.
Risch, N, Merikangas, K. The future of genetic studies of complex human diseases. Science 1996, 273:1516–1517.
Genomics OoP. Catalogue of published Genome‐Wide Association Studies. National Human Genome Research Institute, NIH [web page]. 2011, second quarter. Available at: http://www.genome.gov/gwastudies/. (Accessed March 27, 2012).
Zuk, O, Hechter, E, Sunyaev, SR, Lander, ES. The mystery of missing heritability: genetic interactions create phantom heritability. Proc Natl Acad Sci U S A 2012, 109:1193–1198.
Relling, MV, Klein, TE. CPIC: clinical pharmacogenetics implementation consortium of the pharmacogenomics research network. Clin Pharmacol Ther 2011, 89:464–467.
Raby, BA. Genetic mapping of pharmacogenetic regulatory variation. Curr Pharm Des 2009, 15:3773–3781.
Stossel, TP. The discovery of statins. Cell 2008, 134:903–905.
Baigent, C, Blackwell, L, Emberson, J, Holland, LE, Reith, C, Bhala, N, Peto, R, Barnes, EH, Keech, A, Simes, J, et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta‐analysis of data from 170,000 participants in 26 randomised trials. Lancet 2010, 376:1670–1681.
Chapman, MJ, Carrie, A. Mechanisms of statin‐induced myopathy: a role for the ubiquitin‐proteasome pathway? Arterioscler Thromb Vasc Biol 2005, 25:2441–2444.
Buettner, C, Lecker, SH. Molecular basis for statin‐induced muscle toxicity: implications and possibilities. Pharmacogenomics 2008, 9:1133–1142.
Laaksonen, R, Katajamaa, M, Paiva, H, Sysi‐Aho, M, Saarinen, L, Junni, P, Lutjohann, D, Smet, J, Van Coster, R, Seppanen‐Laakso, T, et al. A systems biology strategy reveals biological pathways and plasma biomarker candidates for potentially toxic statin‐induced changes in muscle. PLoS One 2006, 1:e97.
Yeh, P, Kishony, R. Networks from drug‐drug surfaces. Mol Syst Biol 2007, 3:85.
Tallarida, RJ. An overview of drug combination analysis with isobolograms. J Pharmacol Exp Ther 2006, 319:1–7.
Lehar, J, Zimmermann, GR, Krueger, AS, Molnar, RA, Ledell, JT, Heilbut, AM, Short, GF , 3rd. Giusti, LC, Nolan, GP, Magid, OA, et al. Chemical combination effects predict connectivity in biological systems. Mol Syst Biol 2007, 3:80.
Cokol, M, Chua, HN, Tasan, M, Mutlu, B, Weinstein, ZB, Suzuki, Y, Nergiz, ME, Costanzo, M, Baryshnikova, A, Giaever, G, et al. Systematic exploration of synergistic drug pairs. Mol Syst Biol 2011, 7:544.
Administration USFaD. FDA`s Critical Path Initiative. Silver Spring; 2010.
Buckman, S, Huang, SM, Murphy, S. Medical product development and regulatory science for the 21st century: the critical path vision and its impact on health care. Clin Pharmacol Ther 2007, 81: 141–144.
Mahajan, R, Gupta, K. Adaptive design clinical trials: methodology, challenges and prospect. Indian J Pharmacol 2010, 42:201–207.
European Medicines Agency CfMPfHU. Reflection paper on methodological issues in confirmatory clinical trials planned with an adaptive design, 2007.
Miller, FG, Rosenstein, DL. The therapeutic orientation to clinical trials. N Engl J Med 2003, 348:1383–1386.
Miller, R, Ewy, W, Corrigan, BW, Ouellet, D, Hermann, D, Kowalski, KG, Lockwood, P, Koup, JR, Donevan, S, El‐Kattan, A, et al. How modeling and simulation have enhanced decision making in new drug development. J Pharmacokinet Pharmacodyn 2005, 32:185–197.
Peck, CC. Quantitative clinical pharmacology is transforming drug regulation. J Pharmacokinet Pharmacodyn 2010, 37:617–628.
Lesko, LJ. Paving the critical path: how can clinical pharmacology help achieve the vision? Clin Pharmacol Ther 2007, 81:170–177.
Sheiner, LB, Beal, SL, Sambol, NC. Study designs for dose‐ranging. Clin Pharmacol Ther 1989, 46:63–77.
Lee, JA, Chu, S, Willard, FS, Cox, KL, Sells Galvin, RJ, Peery, RB, Oliver, SE, Oler, J, Meredith, TD, Heidler, SA, et al. Open innovation for phenotypic drug discovery: The PD2 assay panel. J Biomol Screen 2011, 16:588–602.
Berry, DA. Bayesian clinical trials. Nat Rev Drug Discov 2006, 5:27–36.
Wang, SJ, O`Neill, RT, Hung, HJ. Statistical considerations in evaluating pharmacogenomics‐based clinical effect for confirmatory trials. Clin Trials 2010, 7:525–536.
Antman, EM, Giugliano, RP, Gibson, CM, McCabe, CH, Coussement, P, Kleiman, NS, Vahanian, A, Adgey, AA, Menown, I, Rupprecht, HJ, et al. Abciximab facilitates the rate and extent of thrombolysis: results of the thrombolysis in myocardial infarction (TIMI) 14 trial. The TIMI 14 Investigators. Circulation 1999, 99:2720–2732.
Antman, EM, Gibson, CM, de Lemos, JA, Giugliano, RP, McCabe, CH, Coussement, P, Menown, I, Nienaber, CA, Rehders, TC, Frey, MJ, et al. Combination reperfusion therapy with abciximab and reduced dose reteplase: results from TIMI 14. The Thrombolysis in Myocardial Infarction (TIMI) 14 Investigators. Eur Heart J 2000, 21:1944–1953.
Topol, EJ. Reperfusion therapy for acute myocardial infarction with fibrinolytic therapy or combination reduced fibrinolytic therapy and platelet glycoprotein IIb/IIIa inhibition: the GUSTO V randomised trial. Lancet 2001, 357:1905–1914.
Salazar, DE, Mendell, J, Kastrissios, H, Green, M, Carrothers, TJ, Song, S, Patel, I, Bocanegra, TS, Antman, EM, Giugliano, RP, et al. Modelling and simulation of edoxaban exposure and response relationships in patients with atrial fibrillation. Thromb Haemost 2012, 107:925–936.
Ruff, CT, Giugliano, RP, Antman, EM, Crugnale, SE, Bocanegra, T, Mercuri, M, Hanyok, J, Patel, I, Shi, M, Salazar, D, et al. Evaluation of the novel factor Xa inhibitor edoxaban compared with warfarin in patients with atrial fibrillation: design and rationale for the Effective aNticoaGulation with factor xA next GEneration in Atrial Fibrillation‐Thrombolysis In Myocardial Infarction study 48 (ENGAGE AF‐TIMI 48). Am Heart J 2010, 160:635–641.
Riesmeyer, JS, Salazar, DE, Weerakkody, GJ, Ni, L, Wrishko, RE, Ernest, CS 2nd, Luo, J, Li, YG, Small, DS, Rohatagi, S, et al. Relationship Between Exposure to Prasugrel Active Metabolite and Clinical Outcomes in the TRITON‐TIMI 38 Substudy. J Clin Pharmacol 2011, Epub ahead of print June 20. doi:10.1177/009127001406280.
Ivy, SP, Siu, LL, Garrett‐Mayer, E, Rubinstein, L. Approaches to phase 1 clinical trial design focused on safety, efficiency, and selected patient populations: a report from the clinical trial design task force of the national cancer institute investigational drug steering committee. Clin Cancer Res 2010, 16:1726–1736.
Simon, R, Freidlin, B, Rubinstein, L, Arbuck, SG, Collins, J, Christian, MC. Accelerated titration designs for phase I clinical trials in oncology. J Natl Cancer Inst 1997, 89:1138–1147.
Ishizuka, N, Ohashi, Y. The continual reassessment method and its applications: a Bayesian methodology for phase I cancer clinical trials. Stat Med 2001, 20:2661–2681.
Gallo, P, Chuang‐Stein, C, Dragalin, V, Gaydos, B, Krams, M, Pinheiro, J. Adaptive designs in clinical drug development—an executive summary of the PhRMA Working Group. J Biopharm Stat 2006, 16:275–283, discussion 285–291,278–293,272–311.
Bretz, F, Koenig, F, Brannath, W, Glimm, E, Posch, M. Adaptive designs for confirmatory clinical trials. Stat Med 2009, 28:1181–1217.
Tournoux‐Facon, C, Rycke, YD, Tubert‐Bitter, P. Targeting population entering phase III trials: a new stratified adaptive phase II design. Stat Med 2011, 30:801–811.
Chow, SC, Corey, R. Benefits, challenges and obstacles of adaptive clinical trial designs. Orphanet J Rare Dis 2011, 6:79.
Barnes, PJ, Pocock, SJ, Magnussen, H, Iqbal, A, Kramer, B, Higgins, M, Lawrence, D. Integrating indacaterol dose selection in a clinical study in COPD using an adaptive seamless design. Pulm Pharmacol Ther 2010, 23:165–171.
Chowdhury, BA, Seymour, SM, Michele, TM, Durmowicz, AG, Liu, D, Rosebraugh, CJ. The risks and benefits of indacaterol–the FDA`s review. N Engl J Med 2011, 365:2247–2249.
Lewis, RJ, Connor, JT, Teerlink, JR, Murphy, JR, Cooper, LT, Hiatt, WR, Brass, EP. Application of adaptive design and decision making to a phase II trial of a phosphodiesterase inhibitor for the treatment of intermittent claudication. Trials 2011, 12:134.
Chapman, PB, Hauschild, A, Robert, C, Haanen, JB, Ascierto, P, Larkin, J, Dummer, R, Garbe, C, Testori, A, Maio, M, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 2011, 364:2507–2516.
Barker, AD, Sigman, CC, Kelloff, GJ, Hylton, NM, Berry, DA, Esserman, LJ. I‐SPY 2: an adaptive breast cancer trial design in the setting of neoadjuvant chemotherapy. Clin Pharmacol Ther 2009, 86: 97–100.
Mehta, C, Gao, P, Bhatt, DL, Harrington, RA, Skerjanec, S, Ware, JH. Optimizing trial design: sequential, adaptive, and enrichment strategies. Circulation 2009, 119:597–605.
Mehta, CR, Pocock, SJ. Adaptive increase in sample size when interim results are promising: a practical guide with examples. Stat Med 2011, 30:3267–3284.
Dragalin, V. Adaptive designs: terminology and classification. Drug Information Journal 2006, 40:425–435.
Chow, SC, Chang, M. Adaptive design methods in clinical trials—a review. Orphanet J Rare Dis 2008, 3:11.
Gallo, P. Operational challenges in adaptive design implementation. Pharm Stat 2006, 5:119–124.
Hung, HM, O`Neill, RT, Wang, SJ, Lawrence, J. A regulatory view on adaptive/flexible clinical trial design. Biom J 2006, 48:565–573.
Wang, SJ, Hung, HM, O`Neill, R. Regulatory perspectives on multiplicity in adaptive design clinical trials throughout a drug development program. J Biopharm Stat 2011, 21: 846–859.
Cook, T, DeMets, DL. Review of draft FDA adaptive design guidance. J Biopharm Stat 2011, 20:1132–1142.
Yusuf, S, Zhao, F, Mehta, SR, Chrolavicius, S, Tognoni, G, Fox, KK. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST‐segment elevation. N Engl J Med 2001, 345: 494–502.
Investigators, TPT. Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes. The PURSUIT Trial Investigators. Platelet Glycoprotein IIb/IIIa in Unstable Angina: Receptor Suppression Using Integrilin Therapy. N Engl J Med 1998, 339:436–443.
Sheiner, LB. Learning versus confirming in clinical drug development. Clin Pharmacol Ther 1997, 61: 275–291.
Dargie, HJ. Effect of carvedilol on outcome after myocardial infarction in patients with left‐ventricular dysfunction: the CAPRICORN randomised trial. Lancet 2001, 357:1385–1390.
Braunwald, E, Domanski, MJ, Fowler, SE, Geller, NL, Gersh, BJ, Hsia, J, Pfeffer, MA, Rice, MM, Rosenberg, YD, Rouleau, JL. Angiotensin‐converting‐enzyme inhibition in stable coronary artery disease. N Engl J Med 2004, 351:2058–2068.
Food and Drug Administration CfDEaRC, Center for Biologics Evaluation and Research CBER. Guidance for industry non‐inferiority clinical trials. 2010.
Mehta, CR Jemiai, Y. A consultant`s perspective on the regulatory hurdles to adaptive trials Biom J 2006, 48:604–608, discussion 613–622.
Editorial. Adapting to circumstances. Nat Rev Drug Discov 2006, 5:617.